Abstract
Background: Concern for drug‐induced QT prolongation has caused significant investment in QT measurement to safety‐test new compounds. Manual methods are expensive and time‐consuming. Reliable automatic methods would be highly desirable.
Methods: Twelve‐lead Holter recordings were annotated beat‐to‐beat by an automatic algorithm for global QRS onset and T offset. T offset was established from the time of peak T downslope plus a rate‐dependent offset, analogous to the “tangent method,” wherein T offset is determined by extrapolating the T downslope to an intersection with the baseline.
Results and Conclusions: Variances of the beat‐to‐beat QT measurements were in the range 2.5–3.4 ms over three distinct databases, including a large heart failure database. Application to a moxifloxacin/placebo control database of 29 subjects showed excellent results.
Keywords: QT, Holter, 12‐lead, beat‐to‐beat, moxifloxacin
The last two decades have seen a resurgence of interest in ECG repolarization effects. Initially, this interest was driven by research on long QT syndrome (LQTS) and the correlation of long QT intervals with sudden cardiac death. Subsequently, QT prolongation induced by drugs—acquired LQTS—was found to have a similar risk. Concern about acquired LQTS has resulted in extensive QT safety testing for new pharmacologic compounds.
The QT interval is rate, drug, and autonomic tone dependent. Isolation of a drug effect, if it exists, mandates control of, or correction for, changes due to rate and autonomics. A consequence is the need for multiple assessments of the QT interval over extended periods of time, with positive control and placebo arms included. In this context, manual methods are expensive and time‐consuming. Reliable automatic methods would be highly desirable. This report focuses on a successful approach to automated serial QT measurement.
METHODS
The data for this study was acquired from Mortara Instrument H12+ Holter recorders. Twenty‐four hours (sometimes abbreviated) of 12‐lead simultaneous data, sampled @ 1000 s/s, with 3.75 microvolt resolution, constituted each recording. Three separate populations were studied: (1) 32 Mortara Instrument employees (CE group), (2) 384 congestive heart failure patients (HF group), and (3) 29 healthy volunteers in a moxifloxacin/placebo “thorough QT” test (MP group). The MP group was part of larger 3‐way crossover design study, wherein moxifloxacin was used as a positive control for the detection of QT prolongation in a third test compound. Nine total recordings on each subject in this group were used for this study, composed of three consecutive twenty‐four‐hour recordings on placebo, a second group of three consecutive recordings with moxifloxacin (400 mg) given on the start of the second day, and a third group taking a test compound (without detected QT change) on the second day. The seventy‐two‐hour recording periods were separated by at least seven days.
Each of the tested groups included both sexes. Details of the respective profiles are not deemed relevant in this study, as no inferences are drawn from the results regarding particular attributes of any one of the groups.
QT measurement is conventionally a process applied to a single cardiac cycle, possibly averaged. The QT measurement algorithms used in this study are part of the proprietary Mortara Instrument VERITAS algorithm set. The process is multi‐lead, using landmarks determined by the earliest QRS onset and the latest T wave offset. The T wave offset itself is set at the point where the local slope magnitude, derived from the available leads, falls below a threshold proportional to the T amplitude. We will refer to this as the static QT measurement process (QTStat). Although QTStat is a robust, stable, and accurate method, variability does occur in sequential measurements of QT on the same subject. While some of this variability is physiologic (true), some is false. False changes occur primarily because the signal amplitudes/slopes at the end of T have a poor signal‐to‐noise ratio.
Continuous QT measurement (QTCont) is especially appropriate in the context of QT safety testing, where changes in QT are more important than the absolute QT duration. We show in this study that the relative accuracy of QTCont can be improved by using a well‐determined fiducial near, but not at the end of the T wave. We have chosen the point of the maximum downslope (upslope in the case of negative T waves) of the T as the fiducial. In this approach the QTCont interval has two segments: (1) QRS onset to the point of maximum T downslope (QTd) and (2) T downslope to T end (Td‐e). Figure 1 provides an illustration of these segments. The QTd segment captures the majority of QT dynamic behavior and can be measured accurately on a beat‐to‐beat basis. The Td‐e segment exhibits only minor beat‐to‐beat variation and is measured indirectly. The concept is expanded to the multilead environment by substituting the spatial velocity, defined by square root of the sum of squared slopes over the independent leads, for the slope in a single lead.
Figure 1.

Graphic portrayal of QT interval segments used in this study. The onset of the Td‐e interval is at the peak of the spatial velocity (absolute slope) of the descending limb of the T wave.
RR values used for determining cycle length specific averages, and for QT/RR modeling, are a weighted average of individual RR's preceding each beat. The method and rationale of this weighting will be published elsewhere.
The first segment of the QT interval, QTd, is well determined by landmarks at QRS onset and peak T downslope. The second segment, Td‐e, is bounded by peak T downslope and T end. This latter segment is more difficult to measure on a beat‐to‐beat basis. Since the typical magnitude is ∼50 ms, it is a relatively small portion (10–15%) of the total repolarization cycle. Our initiative is to model this small segment to have a linear dependence on cycle length. Our QTCont reflects a direct measure of 85–90% of the repolarization cycle, and a patient‐specific modeling of the remaining 10–15%. The model parameters are the slope of the linear Td‐e/RR dependence and a “pivot” cycle length. Values of Td‐e are determined using average cardiac cycles, wherein the determination of T end (QTStat) is made more robust by the lower noise of the average cycles. Using multiple average cardiac cycles, each average made up of cycles with a preceding RR in a specific range, allows the cycle length dependence of Td‐e to be evaluated. The pivot cycle length is selected from the most populous cycle length range. Expressed algebraically:
and
where “i” is a beat number, T0 is the value of Td‐e(i) at the pivot cycle length (RRp), S2 is the linear slope reflecting Td‐e(i) dependence on cycle length, and RR(i) is the cycle length for a given beat. The Td‐e/RR slope, S2, is derived by least squares from values of QTStat– QTd measured in RR interval selected average cycles at 50 ms increments. T0, S2, and RRp are constants for each twenty‐four‐hour recording.
Not every cardiac cycle will yield a meaningful QTCont. Examples include periods of noisy data, cycles with no identifiable T peak,—without which the downslope is undefined, and ectopic cycles. We also exclude cycles with potential QTCont values more than 30 ms from an “expected” value, determined by an adaptive average of prior measurements. Apart from this last limitation, each value of QTCont is statistically independent. Six percent of the total available cycles were excluded for all of the above reasons in the most extreme case (HF group).
QT/RR slopes were determined for QTCont, using a linear model. The RR interval used was not the prior RR, but a composite, weighted average of previous intervals based on a method to be published separately. The QT/RR slope was obtained from all measured cycles over the full 24 hours.
RESULTS
Table 1 summarizes the significant results from each of the studied populations. The standard deviation (QT‐RMSSD) of QTCont was calculated for each recording as the standard deviation of the successive differences of QTCont over valid cycles, divided by the square root of two, based on the assumption of statistical independence of the each cycle's measurement. 1 To the extent that the true QTCont does not vary significantly on a beat‐to‐beat basis, QT‐RMSSD reflects the measurement error. Table 1 reports the average QT‐RMSSD in each of the different populations, and the 90th percentile value. The proximity of latter to the former is a measure of the consistency within each population. The HF group shows the greatest disparity, and this is attributed to the more complex, lower amplitude, and greater range of T wave morphologies in this group.
Table 1.
Various QT Measures from Study Groups
| Group | CE | MP | HF |
|---|---|---|---|
| Number of subjects | 32 | 29 | 384 |
| Number of recordings | 32 | 261 | 384 |
| QT‐RMSSD (ms) | 3.1 ± 0.8 | 2.5 ± 0.5 | 3.4 ± 1.5 |
| QT‐RMSSD 90th percentile (ms) | 4.3 | 3.7 | 6.1 |
| QT‐RMS (ms) | 6.6 ± 1.4 | 6.1 ± 1.1 | 6.8 ± 2.1 |
| QT/RR slope | 0.20 ± 0.04 | 0.19 ± 0.05 | 0.24 ± 0.07 |
| Td‐e/RR slope | 0.02 ± 0.03 | 0.02 ± 0.02 | 0.04 ± 0.06 |
All measurements are the averages for the groups, apart from the QT‐RMSSD 90th percentile. Standard deviations (±) are included where appropriate.
CE = Company employees; MP = Moxifloxacin/placebo clinical trial; HF = Heart failure group; QT‐RMSSD = Root‐mean‐square of successive differences of QTCont, divided by square root of two; QT‐RMS = Root‐mean‐square deviation of QTCont from linear QT/RR model; QTCont= Beat‐to‐beat QT; QT/RR slope = Least‐mean‐square slope from linear QT/RR model, using individual cycles; Td‐e/RR slope = Linear dependence of the terminal segment of QT on RR interval.
Another perspective on QTCont variation is provided by the root‐mean‐square (RMS) deviation of QTCont from an optimum QT/RR slope (QT‐RMS). The mean values of QT‐RMS from each of the studied populations show little difference (6.1–6.8 ms). QT‐RMS is presumed to reflect primarily the inadequacies of the linear model for QT as function of RR interval and the variation of QT with other physiologic parameters, such as autonomic tone. The values for the MP group include those where moxifloxacin was taken the same day, although this pertains to only 1/9 of the total recordings for the group.
Included in Table 1 are the total QT/RR slope and the Td‐e/RR slope. The total slope values are rather high in all groups, possibly reflecting the use of the weighted RR to derive the slopes. 2 The rate dependence of the terminal Td‐e segment is shown graphically in Figure 2 and observed to be reasonably linear with, and to have only modest dependence on, cycle length.
Figure 2.

Cycle length dependence of terminal QT segment (Td‐e) duration. The mean duration of the Td‐e interval, plotted against cycle length, for each of the three studied populations.
The foregoing methodology has been applied to the MP group data to derive what is known as the “Δ–Δ” plot. This plot is constructed by first subtracting a baseline twenty‐four‐hour period from the rate‐corrected QT (QTc) trend over 24 hours following a drug dose and then subtracting a similar twenty‐four‐hour trend of QT for the placebo less the placebo baseline. Figure 3 shows this plot for our MP data. Sample points are taken at 15‐minute intervals and show one standard deviation limits. Each sample point is derived from the median QTc over valid measures within ± 1 minute of the time point. Rate‐correction was performed using individual QT/RR slopes. The last hour is not plotted due to missing data from some of the recordings. The mean (over all sample points) standard deviation is 2.0 ms.
Figure 3.

Delta‐delta plot showing QT prolongation due to moxifloxacin. Δ–Δ plot ((Moxifloxacin – Moxifloxacin control) – (Placebo – Placebo control)), sampled at 15 minute intervals and showing one standard deviation limits.
Interestingly enough, the dynamic behavior of QTc is not dependent on the Td‐e/RR slope. In the linear QT/RR model,
or
where S1 is the QTd/RR slope. The last two terms above are constants for a given recording, and thus, QTc dynamically depends only on QTd and RR. Consequently, the Δ–Δ plot only has a constant offset when the Td‐e/RR slope correction is applied to the QTd measures (1.2 ms in the present study).
CONCLUSIONS
The results show that the time of the maximum downslope of the T wave can be measured accurately over a diverse population of ECG morphologies, including a large sample of congestive heart failure recordings. Unaccounted for variation of QT was as small as 2.5 ms, and only 3.4 ms in the HF group.
Direct comparison with alternative QT measurement methodologies is hampered by the lack of common databases used for reporting. The use of databases with dissimilar noise levels and T wave morphologies limit the conclusions that may be drawn. Even the definition of QT variation varies—while this study measures the internal consistency of QT values, others use external manual QT measures as the reference. Nevertheless, the results obtained in this study compare favorably with those found by Hnatkova et al., 3 who report a range of QT variation from 5.5 to 9.5 ms from two clinical studies, using healthy volunteers. Moreover, our result of 2.5 ms in a similar population is based on single‐beat measurements, while the former is based on noise‐reduced composite cardiac cycles over 10 seconds.
A litmus test for a successful QT measurement methodology is the appropriate detection of moxifloxacin‐induced QT prolongation in the positive control arm of a drug study. The data in Figure 3 clearly demonstrates such a success. A maximum QT prolongation of 13 ms is observed 4–5 hours after dosage, with a 6 ms residual prolongation after 23 hours. The mean RMS variability is 2.0 ms, with minor fluctuation over the observation period. Remarkably, this result is achieved with only 29 subjects in the study.
Hypothetically, a limitation of the use of the T downslope maximum as a surrogate for T end would occur in a situation where the increase of QT occurs primarily in the Td‐e segment. In all cases where the Td‐e segment changes disproportionately to the other components of the repolarization interval, the extent of QT change will be underestimated.
Conflicts of Interest: None.
Acknowledgments
Acknowledgments: Thanks are due to Terrence Fullerton of Pfizer for providing the MP data set and to the GISSI‐HF investigators 4 for permission to use the HF data set.
REFERENCES
- 1. Glantz S. Primer of Biostatistics, 6th Edition, McGraw Hill, 2005, pp. 77–80. [Google Scholar]
- 2. Coumel P, Fayn J, Maison‐Blanche P, et al Clinical relevance of assessing QT dynamicity in Holter recordings. J Electrocardiogr 1994;27:62–66. [DOI] [PubMed] [Google Scholar]
- 3. Hnatkova K, Gang Y, Batchvarov V, et al Precision of QT measurement by advanced electrocardiographic equipment. Pace 2006;29:1277–1284. [DOI] [PubMed] [Google Scholar]
- 4. Tavazzi L, Tognoni G, Franzosi MG, et al., for the GISSI‐HF Investigators . Rationale and design of the GISSI heart failure trial: A large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635–641. [DOI] [PubMed] [Google Scholar]
